About Aditi Ganguly

Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing.  She has a keen interest in the stock market and has a fundamental approach when analyzing equities.

Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis.  After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww.  Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.


Recent Articles By Aditi Ganguly

: RUN |  News, Ratings, and Charts

4 Green Energy Stocks to GROW Your Portfolio

A combination of catalysts is brewing for green energy companies. This includes a desire to reduce pollution in many countries, an aggresive alt energy stimulus plan proposed by Joe Biden, and increased efficiencies. Green energy companies such as Sunrun (RUN), Workhorse Group (WKHS), Azure Power Global (AZRE), and Pacific Ethanol (PEIX) will outperform in the upcoming years.
: DKNG |  News, Ratings, and Charts

Will Shares of DraftKings Continue to Soar?

Draftkings (DKNG) is well positioned to maintain its momentum even after gaining 200% since its debut, owing to its growth potential, impressive past performance, favorable analyst sentiment and underlying industry strength.
: CMCSA |  News, Ratings, and Charts

An Entertainment Stock Showing Strength Amid Market Weakness

Comcast (CMCSA) is well positioned to move higher owing to its promising business outlook, solid past performance, short- and long-term bullishness and underlying industry strength.
: VGT |  News, Ratings, and Charts

Buy the Dips in These 3 Tech ETFs

The tech industry has dropped by around 15% in September. However, the sector's long-term fundamentals such as earnings growth remain solid. ETFs such as Vanguard Information Tech ETF (VGT), iShares Expanded Tech Software Sector ETF (IGV), and First Trust ISE Cloud computing Index Fund (SKYY) will outperform in the coming months.
: MRK |  News, Ratings, and Charts

Why You Should Add This Vaccine Maker to Your Portfolio Now

Merck’s (MRK) unique approach to developing a coronavirus vaccine may yield better results than its competitors. Further, the stock pays an above-average dividend, has a pipeline of promising drugs, and a track record of developing blockbuster drugs.
: XLY |  News, Ratings, and Charts

3 ETFs to Buy as "Market Rotation" Out of Tech Stocks Begins

With the United States gradually recovering from the pandemic-induced recession, the market rotation out of the high-flying tech sector has started. As the focus has primarily been shifting to consumer discretionary and financial services, the following ETFs should benefit: Consumer Discretionary Select SPDR ETF (XLY), the iShares U.S. Financial Services ETF (IYG), and the Vanguard Small-Cap Value ETF (VBR).
: ABT |  News, Ratings, and Charts

Should You 'Buy the Dip' in Abbott Laboratories?

Abbott Laboratories (ABT) is expected to soar in the upcoming months based on its impressive financial performance, favorable analyst sentiment, and rising demand for its recently launched COVID-19 testing kit.
: TGTX |  News, Ratings, and Charts

3 Biotech Stocks with STRONG Momentum

TG Therapeutics (TGTX), Mesoblast (MESO), and Trillium Therapeutics (TRIL) are close to gaining approval for potentially blockbuster drugs. Their stocks are rising in anticipation. Find out whether you should invest.
: PFE |  News, Ratings, and Charts

Is Pfizer Stock a Buy?

Pfizer (PFE) is one of the leading drug manufacturers that’s in the race for developing a coronavirus vaccine. This, along with its sound financials, make it a good stock to buy right now.
: REGN |  News, Ratings, and Charts

4 Healthcare Stocks with HIGH Profit Margins

Healthcare players such as Regeneron Pharmaceuticals (REGN), Genmab (GMAB), Horizon Therapeutics (HZNP), and Bio-Rad Laboratories (BIO) demonstrated high-profit margins and are expected to witness a surge in their earnings, revenue, and profit margins with the advent of a definitive vaccine for coronavirus.
Page generated in 0.0054 seconds.